AG10

DRUG3 trials

Sponsors

Eidos Therapeutics, a BridgeBio company

Conditions

Amyloid CardiomyopathyFamilial ATTR-CM (ATTRm-CM, or FAC)Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyWild-type ATTR-CM (ATTRwt-CM)

Phase 2

Study of AG10 in Amyloid Cardiomyopathy

CompletedNCT03458130

Eidos Therapeutics, a BridgeBio companyFamilial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)

Start: 2018-04-27End: 2018-10-05Updated: 2022-11-16

Open-Label Study of AG10 in Patients with Cardiomyopathy

Active, not recruitingNCT03536767

Eidos Therapeutics, a BridgeBio companyAmyloid Cardiomyopathy

Start: 2018-08-08End: 2027-07-31Target: 55Updated: 2025-03-13

Phase 3

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

WithdrawnNCT04418024

Eidos Therapeutics, a BridgeBio companyTransthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Start: 2020-10-21End: 2024-04-30Updated: 2024-09-19

Related Papers

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

2026-07-02

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy

Journal of the American College of Cardiology2019-03-15244 citations